2009
DOI: 10.1097/aog.0b013e318190a459
|View full text |Cite
|
Sign up to set email alerts
|

Benefits and Risks of Oral Diabetes Agents Compared With Insulin in Women With Gestational Diabetes

Abstract: No substantial maternal or neonatal outcome differences were found with the use of glyburide or metformin compared with use of insulin in women with GDM.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
82
0
13

Year Published

2009
2009
2018
2018

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 148 publications
(96 citation statements)
references
References 22 publications
1
82
0
13
Order By: Relevance
“…A glibenclamida é considerada a melhor opção entre as sulfonilureias para utilização em gestantes, sendo considerada segura para emprego a partir do segundo trimestre de gestação (10,29,30).…”
Section: Glibenclamidaunclassified
“…A glibenclamida é considerada a melhor opção entre as sulfonilureias para utilização em gestantes, sendo considerada segura para emprego a partir do segundo trimestre de gestação (10,29,30).…”
Section: Glibenclamidaunclassified
“…Их объединенный ана-лиз (4 рандомизированных клинических исследования с участием в общей сложности 1229 беременных) не выявил различий в эффек-тивности контроля гликемии, а также материнских и неонаталь-ных исходах при лечении ГСД пероральными сахароснижающими средствами по сравнению с традиционной стратегией инсулиноте-рапии. Между группами глибенкламида и инсулина не различались частота проведения кесарева сечения, средняя масса тела новорож-денных и частота врожденных аномалий развития [40].…”
Section: /2011unclassified
“…Many research studies attempted to establish the safety and efficacy of oral hypoglycaemic agents (OHA) [16] [17].…”
Section: ) Oral Hypoglycaemic Agents (Oha)mentioning
confidence: 99%